Reduction of low-density lipoproteins with dextran sulfate in patients with familial hypercholesterolemia.
A novel on-line system for the selective precipitation of low-density lipoprotein (LDL) using dextran sulfate has been devised and tested in four patients with heterozygous familial hypercholesterolemia (type II). The mean pretreatment serum cholesterol was 410 mg/dl. Plasma was generated by membrane filtration and LDL and VLDL (very-low-density lipoprotein) were completely precipitated with 10-35 mg% dextran sulfate (Mr 5,000) in the presence of 55 mM Ca2+. The precipitate was removed by filtration and the excess Ca2+ by dialysis. For 41 procedures the mean reduction of plasma solutes was LDL + VLDL 65%, HDL 23%, fibrinogen 19%, albumin 15%, IgG 20%, IgA 19%, IgM 24%. We conclude that dextran sulfate precipitation is an effective method for selective on-line removal of LDL from plasma.
Antwiler
G D
GD
COBE Laboratories, Inc., Lakewood, Colorado 80215.
Dau
P C
PC
Lobdell
D D
DD
D000328:Adult; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003165:Complement System Proteins / Q000378:metabolism; D016264:Dextran Sulfate; D003911:Dextrans / Q000008:administration & dosage*; D005340:Fibrinogen / Q000378:metabolism; D005590:Fractional Precipitation; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D007136:Immunoglobulins / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*
D008078:Cholesterol, LDL; D003911:Dextrans; D007136:Immunoglobulins; D008079:Lipoproteins, VLDL; D005340:Fibrinogen; D003165:Complement System Proteins; D016264:Dextran Sulfate; D002784:Cholesterol